公开(公告)号：US20060167245A1

公开(公告)日：2006-07-27

申请号：US11334478

申请日：2006-01-19

申请人： Wayne Widdison ,  Ravi Chari

发明人： Wayne Widdison ,  Ravi Chari

IPC分类号： C07D491/04

CPC分类号： C07D498/18

摘要： Improved processes for the preparation and purification of maytansinoid esters, especially thiol and disulfide-containing maytansinoids are described. In one aspect the process comprises a process of making a maytansinoid ester comprising forming an anion of maytansinol or a maytansinoid bearing a free C-3 hydroxyl moiety and reacting the anion with an activated carboxyl compound to thereby produce the maytansinoid ester.

摘要翻译： 描述了用于制备和纯化美登木素生物碱酯，特别是硫醇和二硫化物的美登木素生物碱的改进方法。 在一个方面，该方法包括制备美登木素生物碱酯的方法，其包括形成美登醇的阴离子或含有游离C-3羟基部分的美登木素生物碱，并使阴离子与活化的羧基化合物反应，从而产生美登木酯生物酯。

公开(公告)号：US20060122259A1

公开(公告)日：2006-06-08

申请号：US11326504

申请日：2006-01-06

申请人： Ravi Chari ,  Walter Blattler

发明人： Ravi Chari ,  Walter Blattler

IPC分类号： A61K31/337

CPC分类号： C07D305/14 ,  A61K31/337 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6881 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  Y02A50/423 ,  Y02A50/491

摘要： A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.

公开(公告)号：US09505829B2

公开(公告)日：2016-11-29

申请号：US13817721

申请日：2011-08-19

申请人： Susan E. Lacy ,  Jeffrey A. Barbon ,  Meha Chhaya ,  Emma Fung ,  Charles W. Hutchins ,  Diane M. Lang ,  Eve H. Barlow ,  Mary Leddy ,  Ravi Chari

发明人： Susan E. Lacy ,  Jeffrey A. Barbon ,  Meha Chhaya ,  Emma Fung ,  Charles W. Hutchins ,  Diane M. Lang ,  Eve H. Barlow ,  Mary Leddy ,  Ravi Chari

IPC分类号： C07K16/22 ,  A61K39/395

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/566

摘要： The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

摘要翻译： 本公开内容涵盖NGF结合蛋白，特别是嵌合抗体，CDR移植和标准化抗体的抗体，及其制备和使用方法。 本公开的抗体或抗体部分可用于检测NGF和抑制NGF活性，例如在患有NGF活性有害的病症的哺乳动物受试者中。

公开(公告)号：US20140178389A1

公开(公告)日：2014-06-26

申请号：US13940506

申请日：2013-07-12

申请人： Susan E. LACY ,  Lorenzo BENATUIL ,  Meha CHHAYA ,  Emma FUNG ,  Renee MILLER ,  Ravi CHARI ,  Sarah J. HEIGHTON ,  Jacqueline G. BIXBY

发明人： Susan E. LACY ,  Lorenzo BENATUIL ,  Meha CHHAYA ,  Emma FUNG ,  Renee MILLER ,  Ravi CHARI ,  Sarah J. HEIGHTON ,  Jacqueline G. BIXBY

IPC分类号： C07K16/24

CPC分类号： C07K16/245 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

摘要： The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

摘要翻译： 本公开提供了特异性结合IL-1α和IL-1和bgr的结合蛋白。 这些结合蛋白可以组织成DVD-Igs。 这些蛋白质可用于调节IL-1α和/或IL-1和bgr的活性; 并可用于治疗免疫疾病如类风湿性关节炎，骨关节炎，牛皮癣，多发性硬化和其他自身免疫性疾病。 此外，它们在改善和/或治疗患有与IL-1积累相关的疾病或病症的个体中的疼痛的用途。

公开(公告)号：US20140134172A1

公开(公告)日：2014-05-15

申请号：US14068976

申请日：2013-10-31

申请人： Jijie Gu ,  Dominic J. Ambrosi ,  Susan E. Lappe ,  Yingchun Li ,  Jonathan A. Hickson ,  Deanna L. Haasch ,  Supriya Gupta ,  Ravi Chari ,  Camellia Zamiri ,  Louie Naumovski ,  Xianhua Cao

发明人： Jijie Gu ,  Dominic J. Ambrosi ,  Susan E. Lappe ,  Yingchun Li ,  Jonathan A. Hickson ,  Deanna L. Haasch ,  Supriya Gupta ,  Ravi Chari ,  Camellia Zamiri ,  Louie Naumovski ,  Xianhua Cao

IPC分类号： C07K16/28 ,  A61K45/06 ,  C07K16/22 ,  A61K39/395

CPC分类号： C07K16/468 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/525 ,  A61K31/7068 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39591 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

摘要翻译： 本文公开了多价和多特异性结合蛋白，制备结合蛋白的方法及其在诊断，监测，抑制，预防和/或治疗癌症，肿瘤和/或其它血管发生依赖性疾病中的用途，其特征在于异常DLL4和 /或VEGF表达或活性。

公开(公告)号：US20110166319A1

公开(公告)日：2011-07-07

申请号：US12975695

申请日：2010-12-22

申请人： Yong DAI ,  Yong WANG ,  Shengjin JIN ,  Deborah MESHULAM ,  Godfrey AMPHLETT ,  Ravi CHARI ,  Wei ZHANG

发明人： Yong DAI ,  Yong WANG ,  Shengjin JIN ,  Deborah MESHULAM ,  Godfrey AMPHLETT ,  Ravi CHARI ,  Wei ZHANG

IPC分类号： C07K1/107

CPC分类号： C07K16/2803 ,  A61K47/642 ,  A61K47/6803 ,  A61K47/6849 ,  C07K16/00 ,  C07K16/2839 ,  C07K16/2884 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/76

摘要： The invention provides processes for preparing a cell-binding agent chemically coupled to a drug. A first process comprises covalently attaching a linker to a cell-binding agent, an optional purification step, conjugating a drug to the cell-binding agent, a subsequent purification step, and optional holding steps. A second process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent, a subsequent purification step, holding steps, and optionally a tangential flow filtration (TFF) step.

摘要翻译： 本发明提供了制备与药物化学偶联的细胞结合剂的方法。 第一种方法包括将接头共价连接到细胞结合剂，任选的纯化步骤，将药物与细胞结合剂缀合，随后的纯化步骤和任选的保持步骤。 第二种方法包括将接头共价连接到细胞结合剂，纯化步骤，将药物与细胞结合剂缀合，随后的纯化步骤，保持步骤和任选的切向流过滤（TFF）步骤。

公开(公告)号：US20060009462A1

公开(公告)日：2006-01-12

申请号：US11217351

申请日：2005-09-02

申请人： Robert Yongxin ,  Ravi Chari

发明人： Robert Yongxin ,  Ravi Chari

IPC分类号： A61K31/495 ,  C07D241/04

CPC分类号： C07D307/85 ,  A61K31/407 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/675 ,  A61K47/545 ,  A61K47/548 ,  A61K47/60 ,  C07D209/42 ,  C07D209/60 ,  C07D403/14 ,  C07D405/12 ,  C07F9/5728 ,  C07F9/65583 ,  Y02A50/423 ,  Y02A50/491 ,  Y02P20/55

摘要： Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion.

公开(公告)号：US20050085513A1

公开(公告)日：2005-04-21

申请号：US10963711

申请日：2004-10-14

申请人： Erkan Baloglu ,  Michael Miller ,  Ravi Chari

发明人： Erkan Baloglu ,  Michael Miller ,  Ravi Chari

IPC分类号： A61K31/337 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/06 ,  A61P43/00 ,  C07D305/14 ,  C07D407/12 ,  C07D407/14 ,  C07D409/12 ,  A61K31/4025 ,  A61K31/4433 ,  C07D45/02

CPC分类号： C07D407/12 ,  A61K31/337 ,  C07D305/14 ,  C07D407/14 ,  C07D409/12 ,  Y02A50/423 ,  Y02A50/491

摘要： Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a link, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.

摘要翻译： 包括在本发明范围内的有效的紫杉烷类和含有连接基团的紫杉烷类。 还包括细胞毒性剂，其包含与细胞结合剂连接的一种或多种紫杉烷类。 一种用于在所选细胞群体中诱导细胞死亡的治疗组合物，包括：（A）细胞毒性量的一种或多种通过连接体与细胞结合剂共价结合的紫杉烷，和（B）药学上可接受的载体，稀释剂或赋形剂 。 还包括诱导选择的细胞群体中的细胞死亡的方法，包括使靶细胞或含有靶细胞的组织与有效量的包含与细胞结合剂连接的一种或多种紫杉烷的细胞毒性试剂接触。